Related Experiment Video

Updated: May 28, 2026

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Skp2: a novel potential therapeutic target for prostate cancer

Zhiwei Wang1, Daming Gao, Hidefumi Fukushima

  • 1Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.

Biochimica Et Biophysica Acta
|October 4, 2011
PubMed

Insights

S-phase kinase associated protein 2 (Skp2) is crucial in prostate cancer development. Targeting Skp2 offers a promising therapeutic strategy for this common male cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Prostate cancer is a leading cause of cancer-related death in men.
  • Several signaling pathways, including AR, Akt, Wnt, Hh, and Notch, are implicated in prostate cancer pathogenesis.
  • Emerging evidence highlights the role of the F-box protein Skp2 in prostate cancer development and progression.

Purpose of the Study:

  • To review the current literature on the function and regulation of Skp2 in prostate cancer.
  • To explore Skp2 as a potential therapeutic target for prostate cancer treatment.

Main Methods:

  • Literature review of recent studies on Skp2 in prostate cancer.
  • Analysis of Skp2's role in various signaling pathways involved in prostate cancer.

Main Results:

  • Skp2 (S-phase kinase associated protein 2) is identified as a critical oncoprotein in prostate cancer.
  • Skp2's function and regulation are key factors in prostate cancer pathogenesis.
  • Skp2 presents a potential therapeutic target for intervention.

Conclusions:

  • Skp2 plays a significant role in the development and progression of prostate cancer.
  • Targeting Skp2 may offer a novel therapeutic approach with significant impact.
  • Further development of Skp2-targeting agents is warranted for prostate cancer treatment.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...